Founded by experts in RNA delivery, Guide Therapeutics has assembled a team of specialists in manufacturing, target selection, drug development, and business development.
BOARD OF DIRECTORS
James Dahlman is a professor in the Department of Biomedical Engineering at Georgia Tech and Emory Medical School. He studied CRISPR with Feng Zhang at the Broad Institute and received his PhD from MIT and Harvard Medical School, studying RNA delivery with Robert Langer. The Dahlman Lab works at the interface of drug delivery, nanotechnology, and genomics, in order to bridge big data and nanomedicine. James has won international awards at every stage of his career, most recently the MIT Tech Review TR35 and World Economic Forum top 10 Emerging Technologies. He has won young investigator awards from BMES, CMBE, Parkinson’s Foundation, and other organizations, and has published papers on drug delivery in Scientific American, Cell, Nature Biotechnology, Nature Nanotechnology, Nature Cell Biology, Nature Metabolism, Science Translational Medicine, Advanced Materials, JACS, PNAS, and other high-impact journals.
Andrew Perlman is Managing Partner at GreatPoint Ventures. He was previously CEO of GreatPoint Energy, which developed technology to convert dirty coal into clean natural gas. During this time, he helped set the record for the most capital raised in China by a U.S. venture-backed company. Andrew is also co-founder of Jetti Resources, a developer of cutting-edge technology to help the mining industry extract vast trapped copper resources. Previously, Andrew co-founded two pharmaceutical companies that went public on the NASDAQ, Zafgen and Sirtris Pharmaceuticals. Andrew has been profiled by the Wall Street Journal as one of its leading young entrepreneurs “on the move,” chosen by the MIT Technology Review as one of its “35 Innovators Under 35,” and selected by Crain’s Chicago Business as one of its “40 leaders under 40.”
Prior to co-founding Biomatics Capital Partners in 2016, Julie was director of Program Related Investments for the Bill & Melinda Gates Foundation. She led the foundation’s $1.5 billion strategic investment pool, which focused on global health, global development and education. She funded 50 investments, including 30 in health care, and built a team of 10 investment professionals.
Julie also chaired Bill & Melinda Gates Foundation’s investment committee, which reviews all program-related investments. Prior to that role, she advised foundations, development finance institutions and governments on venture capital, SME financing and technical assistance programs. She holds a B.A. from Harvard University, an MBA from Wharton Business School and an M.A. from Johns Hopkins School of Advanced International Studies.